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Background: Inflammation induced by oxidized low-density lipoprotein (ox-LDL) plays an important role in the
pathogenesis of atherosclerosis. Recently, roles of autophagy against inflammation in the process of atherosclerosis
have drawn increasing attention. Here, we tested the possible molecular mechanisms by which berberine confers
an anti-inflammatory effect in macrophages by upregulation of autophagy.
Methods: J774A.1 macrophages were incubated with various doses of ox-LDL for various times. We evaluated the
inflammatory factors and autophagy proteins (LC3II/LC3I, and SQSTM1/p62) to ascertain the optimal dose and time.
Ox-LDL–induced inflammatory factors and autophagy in J774A.1 cells were tested by the AimPlex multiplex assay,
Western blotting, confocal microscopy, and transmission electron microscopy in the presence of berberine or
chloroquine (CQ). Adenosine 5’-monophosphate-activated protein kinase (AMPK) inhibitor compound C was used
to evaluate the AMPK/mTOR signaling pathway.
Results: Berberine dose- and time-dependently reduced ox-LDL–induced inflammation and increased the ratio of
LC3II/LC3I, and SQSTM1/p62 in J774A.1 cells. CQ significantly attenuated the berberine-induced autophagy and
anti-inflammation. In addition, berberine increased the ratio of p-AMPK/AMPK and decreased the ratio of p-mTOR/
mTOR. AMPK inhibitor compound C abolished berberine-induced autophagy and promoted p-mTOR/mTOR expression
in J774A.1 cells.
Conclusion: Berberine treatment inhibits inflammation in J774A.1 cells by inducing autophagy, which is mediated
through activation of the AMPK/mTOR signaling pathway. Importantly, this study provides new insight into berberine’s
molecular mechanism and its therapeutic potential in the treatment of atherosclerosis.
Keywords: Berberine, Macrophage, Autophagy, Inflammation, AMPK/mTORBackground
Atherosclerosis (AS), an imbalance in lipid metabolism
and a maladaptive inflammatory response, has been
evidenced to be a chronic inflammatory disease of the
arterial wall [1]. Oxidized low-density lipoprotein (ox-
LDL) is a potential inducer of chemokines, which is rec-
ognized as a critical cardiovascular risk [2,3]. Emerging
data have demonstrated that modified lipids engulfed by* Correspondence: ljxunljxun@163.com
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unless otherwise stated.monocyte-derived macrophages resulted in the secretion
of pro-inflammatory cytokines and further macrophages
recruitment. This contributes to robust increases in
atherosclerotic plaque size and complexity [4]. There-
fore, understanding the regulatory mechanisms of in-
flammation in monocytes/macrophages is important for
prevention of AS.
Autophagy is the process in which protein aggregates
and damaged organelles are removed for the maintenance
of intracellular homeostasis during various cell stresses
[5]. Recent studies have highlighted the importance of
autophagy role in the formation of atherosclerosis. It was
demonstrated that autophagy in macrophages plays ais is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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autophagy dysfunction in macrophages leads to the
inflammation and thus accelerates atherosclerotic pro-
gression [7]. Although how autophagy induction affects
pathological processes, such as inflammation, remains
to be elucidated, autophagy might be a novel thera-
peutic strategy for the prevention and treatment of AS
[8]. The enhancement of autophagy in macrophages by
drugs or other methods potentially inhibits the progres-
sion of atherosclerotic plaques and reduces its stability
[9]. Some pharmacological agents have been identified
for modulation of autophagy in AS. The most common
inducer is mTOR inhibitors, such as rapamycin, and its
analogs everolimus. Nowadays, some active components
from natural medicines have been regarded as the focus
in the treatment of AS, such as salvianolic acid B, baica-
lin, tectoridin, etc.
Berberine (BBR) extracted from Coptis, one of the
isoquinoline quaternary alkaloid, has a definite potential
in clinical because of its diverse pharmacological proper-
ties, such as antimicrobial, antidiabetic, antihyperlipi-
demic, anti-inflammatory, and antioxidant [10,11]. Studies
have focused on the therapeutic role of BBR in cardiovas-
cular diseases, especially in coronary heart disease [12].
Additionally, berberine could trigger autophagy in cancer
cells, and its beneficial effects were alleviated when the
autophagy process was genetically or pharmacologically
inactivated, which suggested that autophagy is indispens-
able for the protective effects of berberine [13,14]. How-
ever, the molecular targets by which berberine may exert
its beneficial effects have not been fully elucidated. There-
fore, we aim to investigate whether berberine could induce
autophagy to inhibit secretion of inflammatory factors




The murine cell line J774A.1 were obtained from Institute
of Basic Medical Sciences of Chinese Academy of Medical
Sciences & Cell Resource Center (ATCC Number:CRL-
1592). Cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) (Hyclone, SH30022.01B) supplemented
with 10% fetal bovine serum (Gibco, 10099-141-FBS),
4 mmol/L glutamine, and 100 U/mL penicillin-100 μg/mL
streptomycin. Cultures were maintained at 37°C in a
humidified 5% CO2 incubator. Cells were identified by
their typical cobblestone morphology under microscope.
Cell treatment
All experiments were performed in complete culture
medium to avoid the induction of autophagy via the
serum starvation pathway. J774A.1 derived macrophages
were exposed to ox-LDL (100 mg/L, Yiyuan biotech,China) for 1 h. Meanwhile, cells were treated with the
different concentrations of berberine (110713–201212,
National Institutes for Food and Drug Control, Beijing,
China) for 24 h or berberine (25 μM) for the different
time points without ox-LDL. Cells were also treated with
chloroquine (CQ, 30 μM, c6628, Sigma-Aldrich, USA),
Compound C (CC, 40 μM, sc200689, Santa Cruz Bio-
technology, USA), rapamycin (RAP, 100nM, R0395,
Sigma-Aldrich, USA), L-Leucine (LEU, 5 mM, L8000,
Sigma-Aldrich, USA) for 1 h following the addition of
berberine for 24 h.
Oil red O staining
After treated by ox-LDL, cells were fixed with 10%
formalin, followed by rinse with 60% isopropanol and in-
cubation with fresh-filtered 0.5% oil red O solution for
10 min at 37°C. For analysis, the cells were washed in
isopropanol for 10 min, rinsed in distilled water, and
hematoxylin was introduced to label the cell nuclei.
Images of cells were captured using a fluorescence
microscope to evaluate the characteristic lipid accumula-
tion in macrophage-derived foam cells. Foam cell forma-
tion was observed under a microscope.
Immunofluorescence microscopy
To assess the alteration and location of target protein,
J774A.1 cells were incubated with anti-LC3 antibody
and anti-p62 antibody (both in 1:500), followed by the
incubation with corresponding secondary antibodies
(1:400), goat anti-rabbit IgG/Alexa Fluor®594 antibody
(Invitrogen, USA) conjugated to LC3 and goat anti-
rabbit IgG/Alexa Fluor®488 antibody (Invitrogen, USA)
conjugated to SQSTM1/P62. Cells were then incubated
with 4’-6-diamidino-2-phenylindole (DAPI, Vector Lab) to
display nucleus. Finally, cells were analyzed with a con-
focal microscope (ZEISS, Germany). Images were digitally
analyzed using ZEN microsystem software to observe the
fluorescence intensity of cells.
Transmission Electron Microscopy
Cells were fixed with 4% glutaraldehyde and post-fixed
in 1% osmium tetroxide at 4°C. The samples were then
washed again, dehydrated with graded alcohol, and em-
bedded in Epon-Araldite resin. 50 nm of ultrathin sec-
tions were obtained using an ultramicrotome (Leica).
Sections were then stained with uranyl acetate and lead
citrate. Hitachi H-7500 transmission electron micro-
scope was used to observe autophagosome.
Bead based multiplex flow cytometry
Aimplex Mouse Inflammation 17-Plex assay kits (Beijing
Quantobio, China, C282217) were used according to the
manufacturer’s instruction manual. Briefly, the assay
procedure consists of a 60 min antigen and capture
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tinylated detection incubation step and a 20 min
streptavidin-PE incubation step. Fluorescence signals of
the sample beads were acquired by a flow cytometer and
the inflammatory factors were analyzed with FCAP
Array 3.0.
Western blotting analysis
Total protein in the supernatant was measured using
bicinchoninic acid (BCA) protein assay kit (P0010-1,
Beyotime, China). Lysates taken from each sample were
separated by 12.5% SDS-PAGE. Blots were probed with
1:1500-diluted primary antibodies against LC3 and
SQSTM1/p62 (L7543 and P0067, Sigma-Aldrich, St.
Louis., MO, USA), AMPKα, p-AMPKα (Thr172), mTOR
and p-mTOR (Ser2448) (5831, 2535, 72949 and 5536,
Cell Signaling Technology, USA) over night at 4°C,
followed by horseradish peroxidase (HRP)-conjugated
secondary antibodies for 90 min at room temperature.
Then, the proteins were visualized by enhanced chemilu-
minescence exposure to Molecular Imager®Gel DocTMXR
+ and ChemiDocTMXRS+ Systems. Finally, the blots were
scanned, and densitometric analysis was performed on the
scanned images using with Image LabTM Software.
Statistical analysis
Results were expressed as mean ± SEM. Statistical sig-
nificance between groups was assessed by one-way ana-
lysis of variance (ANOVA) followed by LSD (Least
Significant Difference) post-hoc test using SPSS Inc.
Tamhane post-hoc test was performed if the variances
were unequal. P < 0.05 or P < 0.01 was considered statis-
tically significant.
Results
The optimal concentration of ox-LDL increased MIP-1α
and RANTES, and decreased IL-10 in J774A.1 cells
To explore the appropriate concentration of ox-LDL at
which could induce inflammatory reaction, we detected
the level of inflammatory factors induced by a series of
concentrations of ox-LDL. Cells were treated with differ-
ent concentrations (0, 25, 50, 100, 150, 200, 300 mg/L)
of ox-LDL for 24 h to induce inflammatory factors.
Figure 1A-B showed that 100 mg/L ox-LDL obviously
increased MIP-1α and RANTES, and decreased IL-10,
compared with other concentrations. Therefore, we
chose 100 mg/L ox-LDL as the optimal concentration
for the subsequent experiments. The flow cytometry
scatter plot of the different concentrations of ox-LDL
was shown in Additional file 1: Figure S1. Meanwhile,
Oil red O staining indicated that J774A.1 cells were in-
duced to foam cells by 100 mg/L ox-LDL (Figure 1C).
Furthermore, we are intended to observe the effect of
ox-LDL on autophagy in macrophages.Autophagy suppressed inflammatory factors induced by
ox-LDL in J774A.1 cells
To demonstrate whether inflammatory factors could be
inhibited by autophagy, we firstly selected different time
points (0.75, 1.5, 3, 6, 12, and 24 h) to observe the effect
of ox-LDL on autophagy induction in J774A.1 cells. The
results showed that ox-LDL increased the expression of
LC3, an indicator of autophagy, in J774A.1 cells, at 0.75,
1.5, 3, and 6 h. Per contra incubation with ox-LDL for
12 h or 24 h declined autophagic activity sharply to the
basal level (Figure 2A-B). For observation of the effect
of berberine on macrophages autophagy, we need to
exclude the basal autophagic effect of ox-LDL on macro-
phages. Considering that 24 h incubation of ox-LDL on
macrophages could both increase inflammatory cyto-
kines and reduce the autophagy level to the base level,
we used 24 h as ox-LDL incubating time in the following
experiments.
Cells were pretreated with CQ (30 μM, a common au-
tophagy inhibitor) for 1 h and then exposed to ox-LDL
for 24 h. We found that the expression of LC3 could not
be inhibited by 3-MA, an autophagy inhibitor which
selectively blocked autophagy during fusion of autopha-
gic vacuoles with lysosomes. However, CQ prevented
autophagy by blocking the degradation of SQSTM1/p62
which was required for the delivery of several ubiquiti-
nated cargos to the autophagosome (Additional file 2:
Figure S2). Therefore, we chose CQ as the autophagy in-
hibitor in subsequent experiments. The results showed
that SQSTM1/p62 was significantly increased by CQ
(Figure 2C-D), and also remarkably increased the secre-
tion of RANTES induced by ox-LDL (Figure 2E-F).
Berberine activated autophagy in dose- and
time-dependence in J774A.1 cells
To determine whether autophagy could be induced by
berberine with a single treatment in J774A.1 cells, we in-
vestigated the ratio of LC3II/LC3I and SQSTM1/p62
degradation. Compared with the control, a single treat-
ment with berberine increased the ratio of LC3II/LC3Iand
decreased SQSTM1/p62 expression in a dose-dependent
(Figure 3A-B) and time-dependent (Figure 3C-D) manner.
With the increase in the concentration of berberine, the
expression of LC3 was evaluated but SQSTM1/p62 deg-
radation was reduced, especially at concentrations of
25 μM and 50 μM. Furthermore, at different time points
(0.75, 1.5, 3, 6, 12 and 24 h) we found that the expression
of LC3 was increased at 3, 6, 12 and 24 h whileSQSTM1/
p62 degradation was decreased at 0.75, 1.5, 3, 6, 12 and
24 h, with the peak at 6 h. Additionally, the levels of LC3
and SQSTM1/p62 were measured in the presence of CQ
to monitor autophagic flux. CQ challenge resulted in fur-
ther accumulation of SQSTM1/p62 in J774A.1 cells before
24 h-incubation with berberine, compared with that in
Figure 1 The changes of inflammatory factors induced by different concentrations of ox-LDL. (A) Cells were incubated with different
concentrations of ox-LDL (0, 25, 50, 100, 150, 200 and 300 mg/L) for 24 h. The levels of MIP-1a, RANTES and IL-10 in the medium were detected
via AimPlex. Points and connecting line graphs showed the quantification of the inflammatory factors. From the curvilinear trend, 100 mg/ L
ox-LDL was the optimal concentration induced the inflammatory factors. (B) Bar graphs showed that 100 mg/L ox-LDL increased the levels of
MIP-1a and RANTES, and decreased the level of IL-10. Values are mean ± SEM. (n = 6). (C) The morphology of J774A.1 cells under normal culture
condition (100×; 200×) or treated with 100 mg/L ox-LDL for 24 h. Oil Red O stainting were used to test the foam cell formation (200×). **P < 0.01 V.S.
control group; *P < 0.05 V.S. control group.
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sults suggested that a single-treatment with berberine pro-
moted cellular autophagic process- in J774A.1 cells.
Berberine prevented ox-LDL-induced inflammation via
up-regulation of autophagy in J774A.1 cells
To investigate whether berberine could inhibit inflam-
matory factors through autophagy induction, we tested the
change of autophagy and inflammatory factors. Comparedwith control group or ox-LDL group, berberine significantly
increased the ratio of LC3II/LC3I and SQSTM1/p62
degradation (Figure 4A-B). After berberine-induced
autophagy was inhibited by CQ, MIP-1α and RANTES
notably increased and IL-10 decreased (Figure 4C-D).
These results indicated that anti-inflammatory effects
of berberine contributed to autophagy in macrophagy
cells. To further confirm berberine-induced autophagy in
J774A.1 cells stimulated by ox-LDL, immunocytochemistry
Figure 2 Endogenous LC3 in the lysates was recognized by immunoblotting with an anti-LC3 antibody. LC3-I, soluble form of LC3;
LC3II, membrane-bound form of LC3. (A) Representative blots of LC3Iand LC3II in J774a.1 cells incubated with 100 mg/L ox-LDL for different
time points (0.75, 1.5, 3, 6, 12 and 24 h) using Western blot analysis. (B) Bar graphs showed the LC3II/ LC3Iratio quantified by Image Lab 3.0 software.
(C) Representative blots of SQSTM1 in the cells incubated by ox-LDL in the presence or absence of 30 μM CQ. (D) Bar graphs showed the band value
of SQSTM1/p62. (E) Representative Flow cytometry scatter plot of J774A.1 cells after treatment with ox-LDL and CQ. (F) The levels of RANTES in the
culture medium were detected via AimPlex. Each experiment was repeated at least three times. **P < 0.01 V.S. control group; ##P < 0.01 V.S. 0.75 h,
1.5 h, 3 h and 6 h groups; $P < 0.05 V.S. ox-LDL group.
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Figure 3 Berberine induced autophagy in J774A.1 cells. (A) Representative blots of LC3 and SQSTM1/p62 in J774A.1 cells treated with a
series of concentrations of berberine (6.25, 12.5, 25 and 50 μM). (B) Bar graphs showed the quantification of endogenous LC3 and SQSTM1.
Experiments were repeated at least three times. (C) Representative blots of LC3 and SQSTM1/p62 in J774A.1 cells treated with 25 μM berberine
for different time intervals (0.75, 1.5, 3, 6, 12 and 24 h). (D) Bar graphs showed the quantification of endogenous LC3 and SQSTM1. Experiments
were repeated at least three times. (E) Representative blots of oLC3 and SQSTM1/p62 in J774A.1 cells treated with 25 μM berberine in the
presence or absence of 30 μM CQ. (F) Bar graphs showed the quantification of endogenous LC3 and SQSTM1/p62. Data are expressed at the
mean ± SEM in the corresponding area. **P < 0.01 V.S. control group, *P < 0.05 V.S. control group; ##P < 0.01 V.S. 6.25 μM and 12.5 μM groups; $
$P < 0.01 V.S. BBR group.
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LC3 and SQSTM1/p62. Cells in control or ox-LDL
group showed little staining of LC3. In contrast, cells
treated with berberine or berberine plus CQ displayed a
strong positive staining distribution of LC3 (Figure 4E).
For SQSTM1/p62, cells treated with berberine plus CQ
also showed an intensely positive staining of SQSTM1/
p62 (Figure 4F). Ultrastructural changes in cells were
examined with transmission electron microscope (TEM).
TEM images in control and ox-LDL group displayed
normal cytoplasm, characterized by mitochondria, endo-
plasmic reticulum, free ribosomes and irregular nucleus,
as well as few autophagosomes and lysosomes (Figure 4G).In contrast, berberine or berberine plus CQ group dis-
persedly exhibited many autophagosomes at various stages
in cytoplasm. Arrows indicated typical double membrane
autophagosomes containing mitochondria and separated
cytoplasm.
Berberine activated autophagy via AMPK/mTOR pathway
in J774A.1 cells
We further explored whether AMPK/mTOR pathway
was involved in berberine-mediated autophagy in J774A.1
cells. Firstly, cells were treated with mTOR inhibitor
rapamycin (100 nM) or agonist leucine (5 mM) in the
presence or absence of 25 μM BBR. As the Figure 5A-B
Figure 4 (See legend on next page.)
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Figure 4 Berberine attenuated ox-LDL-induced inflammation through the induction of autophagy in J774A.1 cells. (A) Representative
blots of LC3 and SQSTM1/p62 in ox-LDL stimulated J774A.1 cells treated with berberine in the presence or absence of 30 μM CQ. (B) Bar graphs
showed the quantification of the indicated proteins. (C) Representative flow cytometry scatter plot of J774A.1 cells after treatment. Experiments
were repeated at least three times. (D) The levels of MIP-1α, RANTES and IL-10 in the culture media from ox-LDL-stimulated J774A.1 cells were
detected via Aimplex. (n = 4) (E) Cells were double stained by LC3 and DAPI and examined by fluorescence microscopy (200×, 400×). (F) Cells were
double stained by SQSTM1/p62 and DAPI and examined by fluorescence microscopy (200×, 400×). (G) Representative TEM images of J774A.1 cells
Arrows indicated the autophagosomes (30.0 kx, 15.0 kx, 5.0 kx). **P < 0.01 V.S. control group, *P < 0.05 V.S. control group; ##P < 0.01 V.S. ox-LDL group;
$$P < 0.01 V.S. BBR group, $P < 0.05 V.S. BBR group.
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amount of LC3 II/I which was down-regulated more
with the treatment of BBR in the presence of rapamycin.
Conversely, leucine enhanced the level of LC3 II/I
which was also down-regulated by exposure of BBR.
Obviously, the mTOR was involved in the cellular re-
sponse to berberine. In addition, cells were treated with
ox-LDL for 1 h in the presence or absence of 10 μMFigure 5 Berberine induced autophagy in J774A.1 cells was mediated
treated J774A.1 cells which were incubated with mTOR inhibitor rapamycin
quantification of indicated proteins. (C) Representative blots of LC3 and SQ
the presence or absence of 10 μM CC. (D) Bars graphs showed the quantif
and p-mTOR/mTOR in J774A.1 cells treated with berberine in the presenc
of indicated proteins. Experiments were repeated at least three times. **P
ox-LDL group, #P < 0.05 V.S. ox-LDL group; $$P < 0.01 V.S.BBR group, $P < 0.05
bb P <0.01 V.S.L-L group.compound C, an AMPK inhibitor, followed by the treat-
ment with berberine for another 24 h. We detected that
berberine-induced expression of LC3 and SQSTM1/p62
degradation were blocked by pretreatment with com-
pound C (Figure 5C-D). At last, berberine induced
an obvious AMPK activation which was neutralized by
compound C. Meanwhile, berberine decreased the
ratio of p-mTOR (Ser2448)/mTOR (Figure 5E-F). It isby AMPK/mTOR pathway. (A) Representative blots of mTOR in BBR
(Rap) or mTOR agonist leucine (LEU). (B) Bars graphs showed the
STM1/p62 in ox-LDL stimulated J774A.1 cells treated with berberine in
ication of indicated proteins. (E) Representative blots of P-AMPK/AMPK
e or absence of 10 μM CC. (F) Bar graphs showed the quantification
< 0.01 V.S. control group, *P < 0.05 V.S. control group; ##P < 0.01 V.S.
V.S.BBR group; aa P < 0.01 V.S. BBR group, a P < 0.05 V.S. BBR group;
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tribute to berberine-induced autophagy.
Discussion
AS is a seriously worldwide health concern and oxLDL-
induced vascular endothelial injury is a driving force in its
initiation and development [15-17]. Berberine, a natural
compound from Coptis chinensis Franch, has been used
for preventing cardiovascular diseases [18,19], especially
oxLDL-induced macrophage injuries [20-22]. However,
the molecular mechanisms are not fully understood. In
our study, we demonstrated that berberine attenuated
oxLDL-induced inflammatory factors by stimulation of
macrophage autophagy via the AMPK/mTOR signaling
pathway.
Autophagy is an essentially metabolic process in which
damaged or senescent organelles can be removed and
thus basal energy balance can be maintained [23]. Dys-
regulation of autophagy might result in many diseases
including AS [24]. The protective actions of autophagy
in AS have been shown by some studies [25,26]. Under
normal circumstances, increased autophagosome forma-
tion, which is characterized by increases in LC3-II con-
version, occurs during cellular autophagy induction in
cells. LC3, an autophagy protein marker, is converted
from cytosolic LC3-I into enzymatic LC3-II when au-
tophagy is activated; thus, the ratio of LC3-II to LC3-I
can be considered as a standard marker for the detection
of autophagy [27,28]. The conversion of soluble LC3-I to
lipid bound LC3-II is associated with the formation of
autophagosomes and also the amount of LC3-II reflects
the number of autophagosomes [29]. Some researchers
showed that the conversion of LC3-I to LC3-II does
not necessarily result in complete autophagy [30]. In
the later stage of autophagy, LC3-II may degrade by
SQSTM1/p62 which means a complete autophagy [29].
Moreover, autophagosome formation increases au-
tophagic flux, which caused elevation of p62/SQSTM1
protein degradation [31]. To verify whether berberine
could regulate the complete autophagy, we tested the
changes of LC3-II/LC3-I ratio and of p62/SQSTM1
amount. In our studies, we first detected that berberine
decreased inflammation via autophagy-dependent mech-
anism, which was demonstrated by the increased ratio of
LC3II/LC3I and SQSTM1/p62 degradation as well.
In accordance with previous studies [32,33], 100 mg/L
ox-LDL can result in autophagy in J774A.1 cells. It had
been showed that ox-LDL treatment intensified autoph-
agy in human umbilical vein endothelial cells. The up-
regulation of both LC3-II and beclin-1 proteins reached
two peaks at 0.5 h and 6 h, and declined at 24 h and
48 h, respectively. While we found that the expression
of LC3II/I induced by ox-LDL did not increase until
12 h and then decreased in J774A.1 cells. The differentchanges of time points may be due to different cell types.
Our results indicated that ox-LDL-induced autophagy
was time-dependent which could become dysfunctional
in advanced stages of AS. Autophagy deficiency pro-
motes AS partially in part through oxidative damage
[34] and inflammation factors release [7]. Furthermore,
our results showed that the autophagy induced by
ox-LDL was decreased further at 12 h and 24 h, which
was consistent with the former report.
It was reported that suppression of autophagy acti-
vated nuclear factor kappa-B (NF-κB) signaling and then
induced TNF-α and IL-6 in THP-1 cells [35]. Our
studies also confirmed that inflammatory factors were in-
creased after autophagy was inhibited by chloroquine
(CQ). Berberine induced autophagy in the way of dose-
and time-dependent manners in J774A.1 cells. At 24 h,
berberine decreased expression of MIP-1α and RANTES,
and increased expression of IL-10, which was prevented
by CQ treatment. After p62/SQSTM1 degradation was
inhibited, the inflammatory factors, MIP-1α and RANTES,
increased but IL-10 decreased. Consequently, berberine
may inhibit inflammation via autopahgy pathway. Another
study showed that the beneficial autophagic process
reduced TNF-induced inflammation and protected the
endothelial cells [36]. Our data also proved this beneficial
autophagic process induced by berberine which might par-
tially inhibited ox-LDL-induced inflammation reaction in
macrophages.
Furthermore, we investigated the potential molecular
mechanisms by which berberine induced autophagy.
AMPK/mTOR is the essential regulator of cellular
autophagy. AMPK is required for the protective effects
of berberine in cardiovascular diseases [37]. Berberine
significantly increased AMPK activity via reactive oxygen
species (ROS) production and knockdown of AMPKα1
abolished the effect of berberine [38]. The mammalian
target of rapamycin (mTOR) kinase is a central inhibi-
tor of autophagy. mTOR consist of mTOR complex 1
(mTORC1) and mTOR complex 2 (mTORC2). mTORC1
is rapamycin sensitive and acts as a major checkpoint that
coordinate the balance between cell growth and autophagy
[39]. Rapamycin, a mTOR inhibitor, suppressed the
amount of LC3 II/I which was downregulated by the
treatment of BBR in the presence of rapamycin. Con-
versely, leucine enhanced the level of LC3 II/I which
was also down-regulated by exposure of BBR. Obvi-
ously, the mTOR was involved in the cellular response
to berberine. We found that pretreatment with com-
pound C increased the expression of p-mTOR/mTOR,
and inhibited LC3 expression and p62/SQSTM1 deg-
radation in oxLDL-stimulated J774A.1 cells. This result
suggested that AMPK might be an upstream factor of
mTOR, and berberine-induced autophagy may be pre-
ceded by the activation of AMPK/mTOR in J774A.1
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mTOR signaling pathway may be involved in berberine-
induced autophagy in macrophage, although the activa-
tion of AMPK/mTOR pathway induced by berberine
has been reported in other cell lines [40,41], our data
demonstrated that the AMPK/mTOR signaling pathway
may be involved in autophagy induced by berberine in
macrophage. In addition, as displayed in Additional file 3:
Figure S3, the mRNA expressions of mTOR was consistent
with the protein levels which indicated that the BBR regu-
lated AMPK/mTOR through transcriptional mechanism.
Additionally, the AMPK/SIRT1 signaling pathway
exerted protective role for AS via autophagy induction
[34,36]. Berberine increased the expression of SIRT1, a
regulator of autophagy, at both the protein and mRNA
levels in macrophages in a dose-dependent manner [42].
However, whether berberine could induce autophagy
through the AMPK/SIRT1 signaling pathway in macro-
phagy cells needs further investigation.
Conclusions
Our results elucidate potential molecular mechanisms
of the anti-inflammatory effects of berberine, in which
autophagy may play an important protective role. Fur-
thermore, the AMPK/mTOR signaling pathway may con-
tribute to the regulation of berberine-induced autophagy.
Additional files
Additional file 1: Figure S1. Representative flow cytometry scatter plot
of the different concentrations of ox-LDL(0, 25, 50, 100,150, 200, 300 mg/L)
for 24h in J774A.1 cells.
Additional file 2: Figure S2. The effect of 3-MA and CQ on J774A.1 cell
lines.
Additional file 3: Figure S3. Quantitative PCR analysis of mTOR mRNA
levels in ox-LDL induced J774A.1 cells treated with BBR, BBR and CC for 24h.
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